Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on AbSci (ABSI – Research Report). The associated price target remains the same with $7.00. Discover ...
https://www.tipranks.com/news/the-fly/dentsply-sirona-to-reposition-byte-business-within-aligner-portfolio Absci (ABSI) and Owkin announced a partnership bringing ...
VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to ...
Absci Corporation (ABSI) announced a strategic collaboration with AMD (AMD) to deploy AMD Instinct accelerators and ROCm software to power critical AI drug discovery workloads, including Absci’s ...
Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on AbSci (ABSI – Research Report) and keeping the price target at $7.00. Discover outperforming stocks and invest ...
Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback